Adalimumab (anti-TNF-α) 

Adalimumab (anti-TNF-α) is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Treatment of HUVECs with Adalimumab for up to 12 hours shows no adverse effect on their cell viability, even with a 10-fold higher concentration of Adalimumab (anti-TNF-α) than used in this study^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

The elimination half-life (t_1/2) of Adalimumab (anti-TNF-α) is long (~20 days)^[1]. The enriched fluorescent-labelled adalimumab (anti-TNF-α) is observed mainly in major Oil red O-positive lesions documenting good tissue penetration of the drug into the atherosclerotic plaque, without background fluorescence of the vessel wall after vehicle control injection into hypercholesterolemic Ldlr^-/- mice^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

331731-18-1

液体

Colorless to light yellow

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ternant D, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015 Feb;79(2):286-97.  [Content Brief]

  [2]. Oberoi R, et al. Targeting Tumor Necrosis Factor-α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. PLoS One. 2016 Jul 28;11(7):e0160145.  [Content Brief]